Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application by Couldwell, William T. & Ragel, Brian T.
J Neurosurg 103:508-517, 2005
Ubiquitous expression of cyclooxygenase-2 in meningiomas 
and decrease in cell growth following in vitro treatment with 
the inhibitor celecoxib: potential therapeutic application
B r ia n  T. R a g k l ,  M.D., R a n d y  L . J e n se n , M.D., P h.D., D avid  L . G i l l e s p ie ,  P h.D.,
S teph en  M . P resco tt , M .D ., P h .D ., and  W illiam  T. C o u l d w e l l , M .D ., P h .D .
D epartment o f  Neurosurgery, University o f  Utah; and H untsman Cancer Institute, Salt Lake City, Utah
Object. Meningiomas are the second most common symptomatic primary central nervous system tumor in adults. Find­
ings of epidemiological studies link meningiomas with a history of head trauma, indicating a causal relationship between 
the inflammatory response and meningioma tumorigenesis. Cyclooxygenase-2 (COX-2), an inducible inflammatory en­
zyme, converts arachidonic acid to prostaglandins, which have angiogenic, cell-proliferative, and antiapoptotic effects. The 
authors investigated COX-2 expression in meningiomas and the effects of celecoxib, a COX-2 inhibitor, on meningioma 
cell growth in vitro.
Methods. Four meningioma surgical specimens were immunohistochemically stained and graded (0 to 4) for COX-2. 
In addition, a Western blot analysis was performed to detect the presence of COX-2. Human meningioma cells grown in 
cell culture were treated with vehicle or celecoxib (0.25-1 mM). An immunohistochemical analysis of COX-2, a methyl- 
thiotetrazole cell proliferation assay, a TUNEL apoptosis assay, and a Western blot analysis for the proapoptotic protein 
BAX were performed in vitro.
One hundred eleven (87%) of 128 benign meningiomas and six (86%) of seven atypical meningiomas displayed a high 
COX-2 immunoreactivity (Grade 4 staining). In the Western blot analysis all four surgical specimens (100%) stained pos­
itive for a 70-kD band consistent with COX-2. Celecoxib inhibited cell growth in a dose-dependent fashion and induced 
apoptosis by Day 2, with no change noted in the expression of the BAX protein.
Conclusions. The COX-2 enzyme is universally expressed in meningiomas. Celecoxib inhibits meningioma growth in 
vitro in a dose-dependent fashion, with evidence of apoptosis. Inhibitors of COX-2 may have a role in the treatment of re­
current meningiomas.
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TV / T  ENINGI0MAS ^  the second most common symp- 
\ / l  tomatic adult central nervous system tumor, ac­
counting for approximately 20% of all primary 
intracranial tumors in adults. Meningioma progression or 
recurrence occurs because of the aggressive biology of the 
tumor or because the lesion is found in an unresectable loca- 
tion.6-27-48 Recurrence rates for benign meningiomas 5 years 
after their complete removal have been reported to be 2 to 
3%, whereas recurrence rates for atypical and anaplastic 
meningiomas have been reported to be 38 to 50% and 33 to 
78%, respectively.1434 Treatment options for recurrent me­
ningiomas include additional surgery, conventional exter- 
nal-beam radiation therapy, stereotactic radiosurgery, and 
systemic therapies.l2-i!-44-45 Unfortunately, radiation therapy 
is limited by radiation neurotoxicity, tumor size, and injury 
to adjacent vascular or cranial nerves.-*-12 To date, chemo-
Abbreviations used in this paper: COX = cyclooxygenase: 
DMSO = dimethyl sulfoxide: DPBS = Dulbecco phosphate-buffered 
saline: MTT = monotetrazolium: NSAID = nonsteroidal antiinflam­
matory drug: TUNEL = terminal deoxynucleotidyl transferase-me­
diated deoxyuridine triphosphate nick-end labeling: WHO = World 
Health Organization.
therapies have proved to be ineffective in controlling re­
current meningiomas and new treatments should be ex- 
plored.5-2'’-44-45-47"
Findings of several epidemiological studies have demon­
strated a link between meningioma tumors and a history of 
head trauma; from this we may infer a causal relationship 
between the inflammatory response and future meningioma 
formation.2-*5-*9'42-4-* Cyclooxygenase-2, an inducible inflam­
matory response enzyme, has been shown to be upregu- 
lated in animal head trauma models.2-*-24 Cyclooxygenase is 
the rate-limiting enzyme in the synthesis of prostaglandins 
from arachidonic acid.-*7 The prostaglandins are involved in 
a variety of biological activities, such as angiogenesis, in­
creased cell proliferation, and suppression of apoptosis. The 
enzyme COX-2 is induced by migratory cells (for exam­
ple, macrophages, monocytes, and microglia) responding to 
proinflammatory stimuli and is considered to be an impor­
tant mediator of acute and chronic inflammatory states.10-1-*-*1 
Overexpression of COX-2 has been closely linked to the tu­
morigenesis of colon, lung, and breast cancers.41-51
A growing body of literature supports the use of NSAIDs 
and selective COX-2 inhibitors in the treatment of an in­
creasing number of cancers. The NSAIDs exert their antiin-
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flammatory action by inhibiting the activity of the COX en­
zyme, which in turn results in decreased synthesis of the 
proinflammatory prostaglandins.13 The ability of NSAIDs 
to inhibit the COX enzyme is considered to be their major, 
but not sole, mode of function.13 Celecoxib (Celebrex; Pfi­
zer, Inc., New York, NY) is a specific COX-2 inhibitor that 
acts slowly, time-dependently, and irreversibly.13
In this article, we demonstrate the ubiquitous expression 
of COX-2 by immunohistochemical staining and Western 
blot analysis and describe our initial findings on the effects 
of celecoxib on meningioma cells grown in vitro.
Materials and Methods
Meningioma Surgical Specimens
Meningioma surgical specimens were obtained in accordance 
with the University of Utah Institutional Review Board protocol and 
were processed for immunohistochemical, cell culture, and Western 
blot analyses. Specimens that were not used for cell cultures were 
stored at — 70°C. Tumors were graded according to WHO criteria.21 
For the purposes of this paper, we will use the term “benign menin­
gioma” to describe a WHO Grade I meningioma.21 Patient data asso­
ciated with paraffin-stained tissue and the in vitro studies are listed 
in Table 1.
Immunohistochemical Staining for COX-2
Four-micrometer-thick paraffin slides containing human menin­
giomas were obtained from the pathology department. Normal dura 
mater (that is, tissue obtained from a patient who underwent tempo­
ral lobectomy for intractable seizures), colon cancer, normal colon, 
breast cancer, and normal breast samples were used as positive and 
negative controls.8 Slides containing tissue were wanned for 20 min­
utes at 35°C and deparafflnized by bathing them with a series of 
xylene and alcohol solutions. We used Vectastain Elite Rabbit Kits 
(Vector Laboratories, Burlingame, CA), following the manufactur­
er’s suggested staining protocol. Briefly, the slides were treated with 
an antigen unmasking solution (Unmasking citrate buffer solution; 
Vector Laboratories), heated in a microwave on high setting for 10 
minutes, and cooled for 20 minutes. The slides were then rinsed with 
DPBS and bathed in a 1% H.0^ solution for 10 minutes to quench 
endogenous peroxidases. This was followed by a DPBS rinse and a 
20-minute treatment with the rabbit blocking solution that was sup­
plied by the manufacturer. After an additional DPBS rinse, the slides 
were incubated overnight at 4°C in primary COX-2 rabbit polyclonal 
antibody (sc-7951; Santa Cruz Engineering, Santa Cruz, CA) at a di­
lution of 1:200. Following an incubation with the primary antibody, 
the slides were rinsed in DPBS and treated with the supplied biotiny- 
lated secondary anti-rabbit antibody for 30 minutes. The tissue was 
again rinsed with DPBS and incubated for 30 minutes with premixed 
avidin-biotin-peroxide complex (ABC; Vector Laboratories). The fi­
nal immunohistochemical staining was performed using the 3,3'di- 
aminobenzidine (DAB; Vector Laboratories) method for 8 minutes 
to obtain a reaction to the ABC. The slides were rinsed in 0.5 M Tris 
buffer at pH 6, counterstained with 1% toluidine blue for 15 seconds, 
and dehydrated by bathing them in a series of increasing concentra­
tions of alcohol and xylene. Permount and eoverslips were then ap­
plied to the slides containing the tissue.
Grading o f Immunohistochemical Staining
The tissue on the slides was graded on the basis of a five-point 
scoring system demonstrating the percentage of cells that demon­
strated stain. The scores were as follows: 0, no staining noted; I, less 
than 1% of cells stained; 2, 1 to 10% of cells stained; 3, 11 to 50% 
of cells stained; and 4, more than 50% of cells stained. This scoring 
system has been described previously.11
Protein Extraction
Isolated COX-2 protein was obtained from surgical specimens
TABLE 1
Characteristics o f 135 patients with meningiomas
Characteristic Value
no. of patients 135




mean 56 ±  15
range 22-88




* Meningiomas were graded according to WHO guidelines.
and meningioma cells grown in vitro. Surgical specimens were ob­
tained from our cryogenic tumor bank. Meningioma cells were 
grown in vitro as described later in this section. Surgical specimens 
(0.3-0.5 g) were homogenized with the aid of a tissue homogenizer 
and 3 ml of tissue homogenizing buffer (10 mM HEPES at pH 7.5, 
2 mM dithiothreitol, 1 mM NaVO„ 1 X protease inhibitor, 100 mM 
NaF, 0.4 mM phenylmethylsulfonyl fluoride, 0.1 mM ethylene- 
glycol-bis (p-aminoethylether)-N,N,N',N'-tetraacetic acid, and 10 
mM Na^PjO,). Cells grown in vitro were rinsed with ice-cold DPBS, 
scraped from the culture dish, pelleted at 580 G for 5 minutes, resus­
pended in 1 ml of homogenizing buffer (DPBS at 7.4 pH, 0.01% NP- 
100, 1 X protease inhibitors), and sonicated for 10 seconds three 
times. Specimens (homogenized surgical specimens or sonicated 
cells grown in vitro) were pelleted at 580 G for 5 minutes at 4°C. The 
supernatant was removed to a new tube and centrifuged a second 
time. The resulting two pellets were combined and 150 to 300 |xl of 
ice-cold lysis buffer (20 mM HEPES at pH 7.5. 400 mM NaCl. 10 
mM NaF, 10 mM 4-nitrophenyl phosphate, 1 mM NaVO„ 0.1 mM 
ethylenediaminetetraacetic acid, 10 |xM NaMoO,,, 10 mM fJ-glyc- 
erophosphate, and 20% glycerol) was added. Glycerol was added to 
the supernatant to make a 5% solution, which was then held on ice 
for 5 minutes and centrifuged at 15,000 G. The resulting nuclear pel­
let was resuspended in three volumes of ice-cold lysis buffer, and 
both nuclear and cytoplasmic fractions were shaken vigorously at 
4°C for 30 minutes. Cellular debris was pelleted by centrifugation at
30,000 G at 4°C for 20 minutes. The nuclear and cytoplasmic super­
natant was removed and stored at — 80°C until use.
Western Blot Analysis for COX-2 and BAX
The total protein concentration of the cellular extract described 
earlier was measured spectrophotometrically in 96-well plates by us­
ing the DC Total Protein Assay (Bio-Rad Laboratories, Hercules, 
CA) and calculated using a benchmark microplate reader (Bio-Rad 
Laboratories). Equal amounts of protein (~ 35 |xg) were resolved 
using sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(4-12% continuous gradient) and transferred to polyvinylidene di­
fluoride Hybond-P membrane (Amersham Pharmacia, Piscataway, 
NY). The membrane was blocked and probed using a COX-2 rabbit 
polyclonal antibody (dilution 1:500, sc-7951; Santa Cruz Engineer­
ing), a BAX mouse monoclonal antibody (dilution 1:100, sc-7480; 
Santa Cruz Engineering), and a mouse immunoglobulin G antiactin 
monoclonal antibody (1:5000 dilution, MAB 1501; Chemicon Inter­
national, Inc., Temecula, CA). The Western blots were visualized us­
ing ECL+ chemiluminescent reagents (Amersham Pharmacia) and 
X-OMAT film (Eastman-Kodak, Rochester, NY).
Meningioma Cell Culture
Tumor specimens were obtained from patients with meningiomas 
and grown in monolayer cultures as described previously.1516 Briefly, 
specimens obtained at surgery were taken immediately from the op­
erating room, digested in collagenase, and placed in Dulbecco mod-
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TABLE 2
Immunoreactivity grades o f  human meningioma specimens 
grown in cell culture and immunohistochemicallv 
stained fo r COX-2
Age (yrs). Sex* Tumor Grade
Immunoreactivity
Grader
61, M, (IOMM-Lee) malignant 4
47, F benign 4
55, M benign 4
38, F benign 4
71, M benign 4
* Age and sex of the patient from when the specimen was obtained, 
t  See Grading o f immunohistochemical Staining for a complete explana­
tion o f staining grades.
ified Eagle medium (Sigma Chemical Co., St. Louis, MO) supple­
mented with 10% fetal calf serum, L-glutamine (2 |xM), penicillin 
(50 IU/ml), and streptomycin (50 mg/ml). The cultured cells were 
maintained at 37°C in 7.5% CO,. Only cells in Passages 1 through 4 
were used in experiments for this study.
Meningiomas grown in vitro have previously been character­
ized on microscopic, immunohistochemical, and ultrastructural lev- 
els.1516-46 According to these studies, cell cultures derived from 
meningioma surgical samples appear to be of leptomeningeal origin. 
This conclusion is based on the cells’ polygonal shape, negative 
staining for glial fibrillary acidic protein, and positive staining for vi­
mentin and epithelial membrane antigen, as well as the presence of 
desmosomes identified using an electron microscope.I>16-46 Low-pas- 
sage cells (that is, cells that have been subcultured no more than four 
times [Passage 4]) were used for these experiments, making fibro­
blast overgrowth less likely. Furthermore, G-band karyotyping was 
performed on four of the six cell lines studied for growth inhibition 
studies, with chromosomal abnormalities typical of meningiomas 
found in three (for example, the loss of chromosomes 22 and 1, and 
the addition of chromosomes 9q and 12q).’ Finally, several cell lines 
used for in vitro experiments were transplanted into the flanks of 
nude mice for in vivo experiments, and histologically these xeno­
graft tumors resemble meningiomas (data not shown).
The human malignant meningioma cell line IOMM-Lee was a 
kind gift from Dr. Ian McCutcheon (M. D. Anderson Cancer Cen­
ter, Houston, TX) and was grown in Dulbecco modified Eagle medi­
um supplemented with 10% fetal calf serum, L-glutamine (2 |xM), 
penicillin (50 IU/ml), and streptomycin (50 mg/ml) at 37°C in 7.5% 
CO,.25
Karyotyping: G-Rand Chromosome Analysis
The IOMM-Lee cell line and three primary meningioma cell lines 
were grown in T-175 flasks to 80% confluence and processed by the 
University of Utah Cytogenetics Laboratory (Salt Lake City, UT) for 
G-band chromosome analysis. All three primary meningioma cell 
cultures were processed for karyotyping by their third cell culture 
passage.
In Vitro Immunohistochemical Staining fo r COX-2
An immunochemical analysis was performed on meningioma 
cells grown in a monolayer culture. The cells were subjected to tryp­
sin treatment, plated in eight-well plastic slides, and allowed to 
remain in growth media for 2 to 3 days as described earlier. The 
EcR293 cell line with an inducible COX-2 vector was also plated for 
u se as a positive control.' After removal of the growth media, metha­
nol maintained at — 10°C was added to each well for 10 minutes. Af­
ter the methanol had been removed, the cells were allowed to air dry 
for 30 minutes at room temperature. The slides were rinsed with 
DPBS and bathed in 1% H ,0, solution for 10 minutes to quench en­
dogenous peroxidases. This was followed by a DPBS rinse and treat­
ment with 10% goat blocking serum for 30 minutes. After an addi­
tional DPBS rinse, the slides were incubated overnight at 4°C in the
primary COX-2 rabbit polyclonal antibody (sc-7951; Santa Cruz En­
gineering) at a dilution of 1:50. Following incubation with the pri­
mary antibody, the slides were rinsed in DPBS and treated with a 
biotinylated secondary anti-rabbit antibody (Vectastain Elite Rab­
bit Kits, Vector Laboratories) for 30 minutes. The slides were again 
rinsed with DPBS and incubated for 30 minutes with premixed 
ABC. The final immunohistochemical staining was accomplished 
using a 10-minute DAB reaction to ABC. The sfides were first rinsed 
in 0.5 M Tris buffer, pH 6, then rinsed in DPBS and distilled H,0, 
and mounted in an aqueous solution.
Celecoxib Preparation
Purified celecoxib was a kind gift from Myriad Genetics, Salt 
Lake City, Utah.,s Celecoxib powder was dissolved in DMSO at 
1000 mM and used as stock solution for all the in vitro experiments. 
A final concentration of 0.1% DMSO was obtained for all experi­
ments.
Growth Inhibition Studies
Growth inhibition studies with varying concentrations of celecox­
ib (0.25-1 mM) were performed on six meningiomas grown in vitro 
(that is, the IOMM-Lee cell line and five benign primary meningi­
omas). Cell counts were determined using both a bright-line hemo- 
cytometer and the MTT assay.
Cells that had been counted using a bright-line hemocytometer 
were placed in 12-well bottom plates at varying densities. The 
IOMM-Lee cell line was plated at a density of 3 X 10’ per well, 
whereas the benign cell lines were plated at densities of 3 to 4 X 104 
per well. Cells were treated in triplicate with either 0.1% DMSO ve­
hicle (control group) or increasing doses of celecoxib (0.25 mM, 0.5 
mM, and 1 mM), Media and drug were changed daily until the cells 
were harvested for cell counts. Cells were harvested at varying time 
points (0, 1, 2, and 3 days) by rinsing the wells with DPBS, dislodg­
ing the cells by incubating them in 0.5 ml of Accutase (MP Biomed­
icals, Irvine, CA) for 1 hour, declumping the cells by pipetting five 
times, and adding 5 |xl of trypan blue before counting the number of 
cells per milliliter; the last step was performed in dupEcate. Cells that 
were colored with trypan blue were excluded.
Cell viability was measured by performing a colorimetric MTT 
assay as recommended by the manufacturer (MTT Cell Proliferation 
Assay; American Type Culture Collection, Manassas, VA). The 
cells were placed in 96-well bottom titer plates at a density of 2 X 
10’ cells per well and treated in triplicate with either 0.1% DMSO 
vehicle (control) or increasing doses of celecoxib (0.25, 0.5, and 1 
mM). The MTT labeling reagent was added at various time points (1,
2, and 3 days) and allowed to react for 2 hours in the cell incubator. 
The supplied MTT detergent was added, and the cells were solubi­
lized overnight at room temperature. A microtiter plate reader was 
used to perform the colorimetric evaluation at 570 nm. Cell viability 
was calculated by performing the MTT assay of absorbance in trip­
licate. Normalized values for the percentage of viable cells were cal­
culated by dividing the cell count in celecoxib-treated groups by the 
mean cell count of three control (DMSO only) groups.
The TUN EL Assay
Meningiomas were grown on plastic slides and treated with vehi­
cle (0.1% DMSO) or 1 mM celecoxib. The cell cultures were fixed 
with 10% formalin on Day 1 or 2 and the TUNEL assay (Promega, 
Madison, WI) was performed as recommended; the fragmented 
DNA of apoptotic cells stained brown.
Expression o f  RAX Protein After Celecoxib Treatment In Vitro
Four meningioma cell lines (IOMM-Lee and three WHO Grade I 
meningiomas) were plated in T-175 flasks, allowed to grow to 80% 
confluence, and treated with vehicle (0.1% DMSO) or 1 mM cele­
coxib for 48 hours. The lanes were loaded with 35 |xg of protein 
from whole-cell lysate and probed with the anti-BAX antibody (23 
kD) as described earlier.
Statistical Analysis
In vitro cell counts were statistically analyzed using the Student
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TABLE 3
lmmunoreaetivity grades o f 135 human meningiomas immunohistochemically stained fo r  COX-2
WHO Tumor Grade
Immunoreactivity Grade— No. (%)*
0 1 2 3 4 Total
benign 0 (0) 0 (0) KD 16(12) 111(82) 128(95)
atypical 0 (0) 0 (0) 0 (0) KD 6 (4 ) 7 (5 )
malignant 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
total 0 (0) 0 (0) 1(1) 17 (13) 117(87) 135(100)
* Grading: 0 and 1 = negative for COX-2; 2 through 4 = positive for COX-2. See Grading o f Immunohistochemical Staining for a 
complete explanation of staining grades.
t-test (unpaired, two-tailed t-test, with confidence intervals set to 
95%) to compare the control and celecoxib-treated groups. Statistical 
significance was set at a probability value less than 0.05 (Prism ver­
sion 4.0: GraphPad Software, Inc., San Diego, CA).
Results
P atien t D em ograph ics and Tum or C haracteristics
O f the 135 patients studied, 64%  w ere w om en and the 
patients ranged in age from 22  to 88 years with a median o f  
56  years (Table I). M ost tumors w ere h isto logically  benign; 
there w ere only seven  atypical and no anaplastic m eningio­
mas. For the in vitro im m unohistochem ical staining studies, 
five cell lines w ere grown in m onolayer cultures. S ixty per­
cent o f  the cell lines had been obtained from male patients; 
the cell lines w ere derived from four benign m eningiom as 
and one malignant (TOMM-Lee) tumor (Table 2 ).25 The 
G-band karyotyping w as performed on three o f  six cell lines  
grown in culture for growth inhibition studies. Karyotyping 
o f  the TOMM-Lee cell line revealed chrom osom al abnor­
m alities that fit the initial description o f  that cell line made 
in 1990 (karyotype: modal number 49  (11 -19).X. — Y, — I, 
add(2)(p 11,2),add(5)(p 13),add(6)(p 13),i(7 )(p  10)X 2 ,ad d (9)  
( q 2 1 ),add( 12 )(q 2 1 ), -  17,add( 14)(q  13),add( 19 ),ad d (20 )).25 
Two o f  three primary m eningiom as analyzed for in vitro 
inhibition studies w ere found to have chrom osom al abnor­
m alities (karyotype o f  a 7 1 -year-old man: modal number 
4 7  (46—48), X ,-Y ,a d d (  1 )(p34),add(4)(p 12 ) ,+ d e l(5 )(q 3 1), 
ad d (6 )(q 2 7 ),+ a d d (9 )(p 2 1 ),add( 12 )(q 2 1 )[cp20]; karyotype 
o f  45-year-old wom an: modal number 4 5 ,X X ,^ 2 2 ;  and 
karyotype o f  a 7 1-year-old wom an: X X,norm al).
Im m unohistochem ical A nalysis o f  CO X -2 in M eningiom as
Im m unohistochem ical staining for C O X -2 w as per­
form ed on 135 human m eningiom a surgical specim ens and 
colon  carcinom a controls.28 One hundred tw enty-eight be­
nign (95% ), seven atypical (5% ), and no (0%) anaplastic 
m eningiom as stained positively  for C O X -2 (Table 3). The 
C O X -2 im m unoreactivity w as found in the cytoplasm  o f  all 
the m eningiom as studied. In fact, 111 (87% ) o f  the 128 be­
nign m eningiom as and six (86% ) o f  the seven atypical m e­
ningiom as exhibited Grade 4  staining (Fig. 1 and Table 3). 
O nly 16 benign m eningiom as (12% ) and one atypical tumor 
(1%) displayed Grade 3 staining, and only one benign tu­
mor (1%) displayed Grade 2 staining (Table 3). N o Grade
0  or 1 stainings w ere noted. Normal dura mater stained for 
C O X -2 displayed staining o f  the endothelial lin ing o f  blood  
vesse ls only (Fig. 1).
The im m unohistochem ical analysis for C O X -2 w as per­
form ed on the TOMM-Lee malignant m eningiom a cell line 
and on four m eningiom as grown in cell culture.25 A ll five  
specim ens exhibited extensive cytoplasm ic and nuclear 
staining (Fig. 2  and Table 2).
E xpression o f  the COX-2 P rotein  in M eningiom as
Four cryogenically stored human m eningiom a sam ples 
w ere processed for Western b lot experim ents. The C O X -2  
protein has a m olecular w eight o f  approxim ately 70  kD."'-L! 
C ytoplasm ic and nuclear protein extracts w ere isolated. All 
the m eningiom as sam pled exhibited staining o f  a large band 
at approxim ately 70  kD  in the cytoplasm  extracts, and three 
o f  four stained positively  in the nuclear extracts (Fig. 3).
C elecoxib-Indue eel A pop to sis  and Inhibition o f  
M eningiom a C ell G row th in C ulture W ithout Change  
in BAX  P rotein  E xpression
The selective C O X -2 inhibitor, celecoxib , decreased m e­
ningiom a cell growth in a dose-dependent fashion in both 
the malignant TOMM-Lee cell line and six benign m e­
ningiom as grown in cell culture (Fig. 4 ). D oses ranging  
from 0 .25 to 1 mM  caused cell growth inhibition, w hich  
increased with higher doses. Statistical significance (p <  
0.05) w as reached when the control group w as compared 
with all treatment groups (that is, groups treated with 0 .25,
0.5, and 1 mM  celecoxib ) by D ay 1.
C elecoxib  (1 m M ) induced apoptosis by D ay 2 as seen in 
the results o f  the T U N E L  assay (Fig. 5). A  m orphological 
analysis o f  the treated cells show ed a decreased m onolayer  
density, reduced cell size, and cell detachm ent from tissue 
culture w ells. T hese findings are consistent with the induc­
tion o f  apoptosis.40 N o change in the expression o f  the pro- 
apoptotic protein B A X  w as demonstrated by Western b lot 
analysis in the TOMM-Lee cell line or in three W H O  Grade
I cell lines (Fig. 6).
Discussion
R ationale fo r  C O X -2 Inhibitors an d  M eningiom as
A lthough the cause o f  m eningiom a is unknown, head  
trauma has been suspected o f  playing a causal role since the 
1800s, with reports o f  m eningiom as develop ing in patients 
at the site o f  prior head trauma. Tn one case report the au­
thors describe the extraction o f  a p iece o f  wire from the cen ­
ter o f  a m eningiom a, its presence the result o f  an explosion  
that had taken place 20  years earlier.42 Several investiga­
tors have show n an increased incidence o f  m eningiom as in 
patients with a history o f  head trauma, with elevated odds
J. Neurosurg. /  Volume 103 /  September, 2005 5 1 1
B. T. Ragel, et al.
Fig. 1. Photomicrographs demonstrating expression of C.OX-2 in human colon cancer and human meningiomas. Pos­
itive immunoreactivity appears as reddish-brown staining. A: Positive control. Strong C.OX-2 immunoreactivity is seen 
in the cytoplasm of colon carcinoma cells (solid arrow). Note that the vascular endothelium stains positively for C.OX-2 
(open arrow). B: Negative control. No staining is noted after slides were incubated with serum only. C.: Normal dura 
mater showing staining of the vascular endothelium only (arrow). D-F: Strong C.OX-2 immunoreactivity noted diffuse­
ly throughout the cytoplasm of meningiomas f solid arrows). Note: monocytes or macrophages within blood vessels stain 
positively (open arrow  in D). Original magnification X 10.
ratios ranging betw een 1.2 and 6 .4 .J9'4’-4J P ossib le causal 
m echanism s o f  m eningiom a form ation fo llow in g  head trau­
m a include inflam m ation, neoplastic changes in m eningeal 
tissue caused by healing, and the release o f  growth factors. 
A ll these factors m ay act as inciting factors in  tum origene- 
sis.-,-‘U9 In fact, it has been suggested  that the form ation o f  
a m eningiom a m ay occur in the setting o f  chronic inflam ­
m ation triggered by head trauma.’ R ecently, the inducible 
inflam m atory enzym e C O X -2 has been show n to be upreg- 
ulated in anim al head trauma m od els.-1’4
C yclooxygen ase is the rate-lim iting enzym e in the syn­
thesis o f  prostaglandins from  arachidonic acid.37 The pros­
taglandins are a diverse group o f  auto- and paracrine 
horm ones that m ediate m any physio- and pathological pro­
cesses. Physiologically , prostaglandins regulate vascular 
hom eostasis, k idney function, ovulation, and parturition. 
T hese com pounds are equally important as mediators o f  in­
flam m ation, throm bosis, and pain.3’ T he form ation o f  pros­
taglandins requires the catalytic activity o f  C O X , w hich  
converts arachidonic acid to the prostaglandin endoperox- 
ide, PG H 2, from  w hich  all other prostaglandins are form ed.
The C O X  enzym e exists as tw o isoform s, C O X -1 and 
COX-2.-’7 T he first, C O X -1, is constitutively expressed in 
m ost tissues and is thought to serve in general “housekeep­
ing” functions (for exam ple, cytoprotection o f  the stom ach  
and platelet aggregation). The second, C O X -2, is induced  
by migratory cells (for exam ple, m acrophages, m onocytes, 
and m icroglia) as a response to proinflamm atory stimuli 
and is considered to be an important mediator o f  acute and
chronic inflam m atory states.LUI Expression o f  C O X -2 has a 
w id e range o f  b io logical activities including angiogenesis, 
cellular proliferation, and the halt o f  apoptosis.10 B oth  en­
zym es are targets for therapeutic N S A ID s.’7
T he ability o f  N S A ID s to inhibit the C O X  enzym e is con ­
sidered to be their major, but not sole, m ode o f  function .| ! 
The N S A ID s decrease C O X  activity through nonselective  
binding, selective binding to C O X -2, or n on cyclooxyge- 
nase C O X -2 m e c h a n ism s .N o n se le c t iv e  C O X  inhibitors 
(for exam ple, aspirin and ibuprofen) are clin ically  lim ited  
by their gastrointestinal and platelet side effects, w hich  are 
attributed to C O X -1 inhibition; therefore, selective C O X -2  
inhibitors w ere developed. C elecoxib  (C elebrex) and ro- 
fecoxib  (V ioxx) are specific C O X -2 inhibitors that act as 
slow , tim e-dependent, irreversible inhibitors o f  C O X -2 .u 
From  a clin ical standpoint, C O X -2 inhibition is expected  
to produce antiinflammatory and analgesic effects w ithout 
causing gastric ulcers or platelet dysfunction.
R elationship B etw een CO X -2 an d  C ancer
Human cancers o f  the bladder, breast, uterine cervix, cen ­
tral nervous system , colorectum , esophagus, head and neck, 
liver, lung, pancreas, prostate, skin, and stom ach overex­
press C O X -2 and produce more prostaglandins than the 
normal healthy tissues from  w hich  they are derived.51 E x ­
perimental evidence has demonstrated that unregulated 
C O X -2 expression occurs at m ultiple stages in carcinogen­
esis and is important in the prom otion o f  tum origenesis.41
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Fig. 2. Expression of COX-2 in EcR293 cells with inducible COX-2 vector (A) and human meningiomas grown in 
monolayer cultures (B-F). Positive immunoreactivity appears as brown staining. A: Positive control. Strong COX-2 im­
munoreactivity is seen in the cytoplasm of COX-2-producing EcR293 cells (arrow). B: Negative control. No staining is 
noted after IOMM-Lee cells were incubated with serum only. C: Extensive staining is seen in IOMM-Lee cells (arrow). 
D-F: Strong COX-2 immunoreactivity (Grade 4) is noted diffusely throughout the cytoplasm and nucleus in three sepa­
rate meningiomas (arrows). Original magnification X 20.
The N S A ID s are important agents for cancer prevention  
and as possib le adjuncts to treatment for the fo llow in g  rea­
sons: 1) C O X  inhibitors stim ulate anticancer effects in v i­
tro; 2) C O X  inhibitors inhibit carcinogenesis in carcino­
gen-induced and genetically  driven rodent m odels; 3) C O X  
inhibitors reduce the incidence o f  colorectal precancerous 
lesions and co lon  cancer (for exam ple, fam ilial adenom a­
tous polyposis); and 4) C O X  inhibitors produce regression  
in precancerous lesions (for exam ple, colorectal aberrant 
crypt fo c i and adenom as, and actinic keratoses o f  the skin) 
in genetic and sporadic cancer risk cohorts.9-51 
Currently, celecoxib  and rofecoxib  are approved by the 
U S  F ood  and Drug Adm inistration for their antiinflam­
matory, analgesic, and cancer-prevention properties in the 
treatment o f  rheum atoid arthritis, osteoarthritis, and fam ilial 
adenom atous p o lyp osis.10-15 On the basis o f  the aforem en­
tioned preclinical and clinical efficacy data obtained in ce le ­
coxib  and rofecoxib and the ubiquitous overexpression o f  
C O X -2 in hum an neoplasia, the National Cancer Institute is 
currently tracking m ore than 20  Phase I, II, and III cancer 
trials on C O X -2 inhibition in the treatment o f  colon , pros­
tate, liver, lung, and breast tumors, and glioblastom a m ulti­
form e (source: National Cancer Institute clinical trials data­
base found at http://w w w .nci.nih.gov/clinicaltrials).
G iven  the loose association o f  m eningiom as w ith a h isto­
ry o f  head trauma, w e  postulated that chronic inflam m ation  
m ay play a role in m eningiom a developm ent and that the 
inflam m atory enzym e C O X -2 m ay b e associated w ith tu- 
m origenesis. I f  these hypotheses are correct, b lockade o f  
C O X -2 m ay hold  therapeutic prom ise for the treatment o f  
m eningiom as.
E xpression o f  CO X -2 in M eningiom as 
W e perform ed an im m unohistochem ical analysis o f  135
paraffin m eningiom a sections and five  m eningiom as grow n  
in vitro for C O X -2 and observed extensive staining in the 
majority o f  the tumors (Fig. 1 and Table 3). T hese findings 
are consistent w ith those o f  tw o other im m unohistochem ­
ical studies, w hich  dem onstrated robust C O X -2 staining in 
m eningiom as. L in and associates26 stained 83 m eningio­
m as for C O X -2 and found that an overw helm ing percentage 
o f  tumors expressed C O X -2. M atsuo, et al.,50 also show ed  
strong C O X -2 im m unoreactivity in six  surgical specim ens. 
Im m unohistochem ical ly, as show n by  our in vitro stainings, 
C O X -2 localizes to both the cytoplasm  and nuclear co m ­
partments. Our paraffin sections w ere counterstained w ith a 
nuclear stain, m aking it d ifficult to localize C O X -2 staining 
to the nucleus. Further proof o f  C O X -2 expression in m e­
ningiom as is supported by  our W estern b lot data.
A  70-kD  band that stained positive for C O X -2 protein  
w as universally seen  in the cytoplasm ic extracts. W estern  
blots for the nuclear extract dem onstrated C O X -2 im m uno­
reactivity in three o f  four m eningiom as. T hese findings lend  
further credence to our im m unohistochem ical data, dem on-
Fig. 3. Western blots of four meningioma tumor samples (num­
bered 1-4). Nuclear (n) and cytoplasmic (c) protein extracts were 
isolated and probed with COX-2 antibody. The COX-2 protein has 
a molecular weight of approximately 70 kD. A large 70-kD band 
stains positively for COX-2 is noted in all samples except one nu­
clear extract (arrow).
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Fig. 4. Effects of varying concentrations of celecoxib (0.25 mM-1 mM) and DMSO vehicle on IOMM-Lee cells (A) 
and benign meningioma cells (B). The DMSO concentration was held constant at 0.1% for all time points. Cell counts 
were determined by bright-line hemocytometer in duplicate, with bars representing the standard error of the mean for three 
separate experiments. Data shown for benign meningiomas (B) are representative of six meningioma cell lines. The t-test 
used to compare control and treated data found a statistical significance between all treatment groups and control by Day 
1 (p <  0.05). The growth curve plateau seen in the control cells of B are due to contact inhibition, a typical feature of be­
nign meningiomas as they reach confluence in vitro.
sta tin g  extensive C O X -2 expression in m eningiom as. The 
presence o f  the 70-kD  C O X -2 protein in  the nuclear extract 
in all but one m eningiom a is an interesting finding, w hich  
w e attribute to an error in our nuclear extraction process.
R ole o f  Celecoxib  in D ecrea sed  M eningiom a C ell 
P roliferation  and Induction o f  A pop tosis
C elecoxib, a selective C O X -2 inhibitor, w as chosen  b e­
cause o f  its approval by the F ood and Drug Adm inistration  
and its superior antigrowth effects in  vitro in  several cell 
lin es.19 55 D ose-dependent inhibition o f  m eningiom a cell v i­
ability by celecoxib  w as seen  in vitro in  both a m alignant 
cell line (IO M M -L ee) and six  benign cell lines. C elecoxib
decreased the growth o f  m eningiom as in  a m onolayer cul­
ture at a dose as lo w  as 0.25 mM ; cell death w as noted by  
D ay 3 at a dose o f  1 m M  in one m eningiom a cell line. T hese  
results are com patible w ith  extensive in  vitro data obtained  
on num erous cell lines, w hich  demonstrate growth inhi­
bition by selective C O X -2 inhibitors.2250 Specifically, in a 
study o f  the g liom a cell lines U 87M G  and U 251M G , the 
C O X -2 inhibitor N S -398  w as show n to inhibit cell prolifer­
ation and m igration.18
The results o f  our study demonstrate that celecoxib  in ­
duces apoptosis in vitro. Yamazaki and colleagues55 show ed  
that in vitro ce lecoxib  inhibited ce ll proliferation and in­
duced apoptosis in colon  cancer cells. Our findings also  
agree w ith those o f  W illiam s, et al.,52 w ho demonstrated that
Fig. 5. Celecoxib induces apoptosis of meningioma cells by Day 2. Apoptosis was assessed using the TUNEL assay. 
A: Negative TUNEL control. B : Positive TUNEL control. C: Drug control, vehicle only (0.1 % DMSO). D: Celecox­
ib (1 mM). Brown staining indicates cells undergoing apoptosis.
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Fig. 6. Western blots of four meningioma cell lines grown in vi­
tro and treated with 0.1% DMSO vehicle control (Con; Lanes 1, 3,
5, and 7) or 1 mM celecoxib (Tx; Lanes 2 ,4 , 6, and 8) for 48 hours. 
The cell lines tested in vitro included a malignant meningioma 
(IOMM-Lee; Lanes 1 and 2) and three WHO Grade I cell lines 
(Samples A-C; Lanes 3-8). Lanes were loaded with 35 (xg of pro­
tein from whole-cell lysate and probed with anti-BAX antibody (23 
kD). The IOMM-Lee cell line (Lanes 1 and 2) and all three WHO 
Grade I meningiomas (Lanes 3-8) displayed no noticeable change 
in BAX expression.
ce lecox ib  potently induced apoptosis and inhibited progres­
sion o f  the ce ll cyc le  in colorectal carcinom a cells grow n in 
culture. Interestingly, the investigators demonstrated that 
these effects w ere brought about by m echanism s indepen­
dent o f  C O X -2 inhibition. In other in vitro studies research­
ers have show n that C O X -2 overexpression results in re­
sistance to apoptosis, w hich  in turn leads to dysregulation  
o f  normal cell death.50-51 A lthough the specific antiapoptotic 
m echanism s remain unclear, one possibility is m odulation  
o f  the B A X -to -b c l-2  ratio, w hich  is k ey  in driving cell 
apoptosis. Prostaglandin E 2 increases bcl-2, resulting in a 
B A X -to -b c l-2  ratio and favoring an antiapoptotic e ffect.10 
In contrast, C O X -2 inhibitors increase the levels o f  B A X  
and decrease those o f  bcl-2, thus favoring ce ll apoptosis.IA 
a s ' Qur in vitro W estern blot studies for B A X  demonstrat­
ed  no change in the expression o f  this proapoptotic protein. 
This finding coincides w ith  those o f  several other studies 
that demonstrated no change in B A X  expression after c e le ­
coxib  treatment.-'LU54 Interestingly, other investigators have  
demonstrated that ce lecox ib  induces the translocation o f  
B A X  from  the cy toso l to the m itochondria by the sim ulta­
neous release o f  cytochrom e C .56 M itochondrial release o f  
cytochrom e C is a know n trigger for caspase pathway acti­
vation and ultim ate apoptosis.56 G iven our findings, it is un­
clear w hether the apoptotic and halt-of-cell-progression e f­
fects that ce lecox ib  had on m eningiom as in this study are 
B A X  dependent.
In Vitro C elecoxib  Treatm ent
The plasm a half-life o f  celecoxib  is 13 hours, w ith a 
steady state reached at 5 days."-20-49 T he range o f  our in vitro 
concentrations o f  ce lecox ib  w as 0.25 m M  to I m M , w hich  
is at least 10 tim es higher than plasm a levels obtained using  
standard dosing in hum ans. Growth studies accom plished at 
low er doses o f  ce lecox ib  had no effect on ce ll grow th in v i­
tro w ithin the relatively short tim e frame tested, m aking the 
higher dosing regim en necessary (data not show n). Current­
ly, in v ivo  experim ents at therapeutically achievable ce le ­
coxib  plasm a levels are being conducted in our laboratory 
w ith prom ising results (data not show n). Our findings o f  a 
discrepancy betw een the h igh  in vitro drug dosing regim en  
and the lo w  (clin ically  relevant) in v ivo  drug regim en agree 
w ith the findings o f  other investigators.52
In this paper w e  do not address the roles o f  C O X -2 ex ­
pression and its inhibition in m eningiom a tum origenesis. In 
fact, m any investigators suggest that ce lecox ib  exerts its 
antitumor effects via pathways other than its blockade o f  
C O X -2. A dditional studies in our laboratory are underway  
to delineate the role C O X -2 plays in tum origenesis and 
whether its blockade by celecoxib  is necessary for the anti­
tumor effects seen in vitro. D espite these shortcom ings, w e  
propose that ce lecox ib  and other N SA ID s m ay have a role 
in the treatment o f  recalcitrant m eningiom as.
Conclusions
T he C O X -2 enzym e is universally expressed in m enin­
giom as. C elecoxib  inhibits m eningiom a grow th in vitro in 
a dose-dependent fashion, w ith evidence o f  apoptosis. The 
C O X -2 inhibitors m ay have a potential role in the treatment 
o f  recurrent m eningiom as.
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